These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 20631706)
41. AIDS/HIV. A boost for HIV vaccine design. Burton DR; Weiss RA Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840 [No Abstract] [Full Text] [Related]
42. Synthetic carbohydrate antigens for HIV vaccine design. Wang LX Curr Opin Chem Biol; 2013 Dec; 17(6):997-1005. PubMed ID: 24466581 [TBL] [Abstract][Full Text] [Related]
43. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. Bradley T; Trama A; Tumba N; Gray E; Lu X; Madani N; Jahanbakhsh F; Eaton A; Xia SM; Parks R; Lloyd KE; Sutherland LL; Scearce RM; Bowman CM; Barnett S; Abdool-Karim SS; Boyd SD; Melillo B; Smith AB; Sodroski J; Kepler TB; Alam SM; Gao F; Bonsignori M; Liao HX; Moody MA; Montefiori D; Santra S; Morris L; Haynes BF EBioMedicine; 2016 Oct; 12():196-207. PubMed ID: 27612593 [TBL] [Abstract][Full Text] [Related]
44. Human immunodeficiency virus antibodies and the vaccine problem. Chiodi F; Weiss RA J Intern Med; 2014 May; 275(5):444-55. PubMed ID: 24581142 [TBL] [Abstract][Full Text] [Related]
45. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809 [TBL] [Abstract][Full Text] [Related]
46. Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Hutnick NA; Myles DJ; Bian CB; Muthumani K; Weiner DB Curr Opin Virol; 2011 Oct; 1(4):233-40. PubMed ID: 22440782 [TBL] [Abstract][Full Text] [Related]
47. Support for the RV144 HIV vaccine trial. Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455 [No Abstract] [Full Text] [Related]
48. Vaccines for the prevention of HIV-1 disease. Mascola JR; Nabel GJ Curr Opin Immunol; 2001 Aug; 13(4):489-95. PubMed ID: 11498307 [TBL] [Abstract][Full Text] [Related]
49. Stabilization and formulation of a recombinant Human Cytomegalovirus vector for use as a candidate HIV-1 vaccine. Kumru OS; Saleh-Birdjandi S; Antunez LR; Sayeed E; Robinson D; van den Worm S; Diemer GS; Perez W; Caposio P; Früh K; Joshi SB; Volkin DB Vaccine; 2019 Oct; 37(44):6696-6706. PubMed ID: 31548012 [TBL] [Abstract][Full Text] [Related]
50. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745 [TBL] [Abstract][Full Text] [Related]
51. Mapping the future of HIV vaccines. Nabel GJ Nat Rev Microbiol; 2007 Jul; 5(7):482-4. PubMed ID: 17571457 [No Abstract] [Full Text] [Related]
52. HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity. Wren L; Kent SJ Hum Vaccin; 2011 Apr; 7(4):466-73. PubMed ID: 21389779 [TBL] [Abstract][Full Text] [Related]
53. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Xu L; Pegu A; Rao E; Doria-Rose N; Beninga J; McKee K; Lord DM; Wei RR; Deng G; Louder M; Schmidt SD; Mankoff Z; Wu L; Asokan M; Beil C; Lange C; Leuschner WD; Kruip J; Sendak R; Kwon YD; Zhou T; Chen X; Bailer RT; Wang K; Choe M; Tartaglia LJ; Barouch DH; O'Dell S; Todd JP; Burton DR; Roederer M; Connors M; Koup RA; Kwong PD; Yang ZY; Mascola JR; Nabel GJ Science; 2017 Oct; 358(6359):85-90. PubMed ID: 28931639 [TBL] [Abstract][Full Text] [Related]
54. Development of a DNA-MVA/HIVA vaccine for Kenya. Hanke T; McMichael AJ; Mwau M; Wee EG; Ceberej I; Patel S; Sutton J; Tomlinson M; Samuel RV Vaccine; 2002 May; 20(15):1995-8. PubMed ID: 11983261 [TBL] [Abstract][Full Text] [Related]
55. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies. Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348 [TBL] [Abstract][Full Text] [Related]
56. Antibodies in HIV-1 vaccine development and therapy. Klein F; Mouquet H; Dosenovic P; Scheid JF; Scharf L; Nussenzweig MC Science; 2013 Sep; 341(6151):1199-204. PubMed ID: 24031012 [TBL] [Abstract][Full Text] [Related]
57. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus. van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570 [TBL] [Abstract][Full Text] [Related]
59. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha. Jiang W; Ren L; Jin N J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910 [TBL] [Abstract][Full Text] [Related]
60. A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials. Zolla-Pazner S; Michael NL; Kim JH Lancet HIV; 2021 Jul; 8(7):e449-e452. PubMed ID: 34029515 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]